Feb 2024

Celix Pharma announces the launch of Vecicom® (Tapentadol) Prolonged-release (PR) tablets 

Celix Pharma is pleased to announce the launch of Vecicom® (Tapentadol) Celix Prolonged-release (PR) tablets. Vecicom® (Tapentadol) 50mg, 100mg, 150mg, 200mg and 250mg PR tablets are supplied in blister packs containing 28 or 56 tablets. 

Vecicom® (Tapentadol) PR Tablets are indicated for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics (#). 

Tapentadol is a narcotic (opioid) that combines two roles of action; it works in the brain and nervous system by binding to receptors thereby reducing pain message travelling to the brain and increasing pain killing messages from the brain(1). 

Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Tapentadol is Celix Pharma’s first scheduled drug (controlled substance) on the market, with several more in our pipeline as we dig deeper into this space which has high compliance barriers, from development to manufacturing and distribution. Really pleased with this critical addition to our portfolio.” 

Shantreddy, Co-founder & COO stated, “Tapentadol has been a challenging project on several fronts, so very happy to see the product enter the market successfully. As always, I would like to thank our partners for their support in making this launch possible.”

#Opioids, like Tapentadol, come with a risk of dependence and addiction. Use of the product should be based on the updated safety advice from the MHRA/CHM (https://bnf.nice.org.uk/drugs/tapentadol/)  

Source:

1 https://www.wwl.nhs.uk/media/.leaflets/60f699e26445d7.23567395.pdf